BioVoice News June 2016 Issue 2 Volume 1 - Page 39

We are in an age where Indian biotechnology companies , mostly perceived as generic manufacturers of blockbuster drugs without patent protection , are breaking the mould to innovate and develop products and technologies that are contributing to the advancement of global healthcare .

“ biotechnology companies , mostly perceived as generic manufacturers of blockbuster drugs without patent protection , are breaking the mould to innovate and develop products and technologies that are contributing to the advancement of global healthcare . With genomics being the future of healthcare , MedGenome has a great opportunity to be a global player .

What kind of analytical and algorithmic pipelines are being built by the company to interpret genomics data ? What makes them different than the competition ?
MedGenome ’ s bioinformatics expertise offers end-to-end data analysis of next generation data using proprietary interpretation tools and algorithms . Our algorithm and analytical pipeline includes various in-house tools for comprehensive high-throughput annotation tool for analysis of germ line and somatic variants , high performance webbased tools for variant interpretation , tools to capture patient information including the clinical symptoms of the patients enabling clinicians to catalogue phenotype in formation of the patient in a systematic and controlled manner , software platform with a modular architecture for handling next-generation genomic sequencing pipeline from data generation to analysis and various proprietary databases such as the one with India population specific variant data and the one with millions of somatic cancer variant annotations .
Our analysis components include data quality assessment , comprehensive custom analysis , interpretation of results for biological
We are in an age where Indian biotechnology companies , mostly perceived as generic manufacturers of blockbuster drugs without patent protection , are breaking the mould to innovate and develop products and technologies that are contributing to the advancement of global healthcare .
insights , and presentation of results to the customers in meaningful , easily readable report formats . Being a leader in diagnostics and research from India , MedGenome continuously refines and improves the pipeline to make the analysis more powerful .
Which of the top disease areas are under the company ' s focus and why ?
MedGenome offers more than 278 tests across different disease areas : Cardiology , Metabolic disorders , Haematology , Ophthalmology , Neurology , Nephrology , Oncology , other rare disorders etc . We also address important research questions in hereditary diseases . As of now the company is extensively focusing on the problems that are affecting the population at large such as cancer , diabetes , cardiovascular diseases , eye disorders , neurological and blood disorders . We have developed specific gene panels that can identify mutations mostly found in the Indian population .
How is the next generation sequencing shaping up , its future trends and effect on the overall drug discovery efforts ?
Genomics has seen rapid advances in the technology of decoding the DNA , triggering a revolution in our ability to understand the genetic and molecular basis of health and disease . The evolution of Next Generation
Sequencing ( NGS ) has significantly reduced the time and cost for genome analysis . These advances have highlighted its relevance in exploratory research and drug discovery , and have translated to a significant influx of capital into the molecular diagnostics firms due to their cutting edge technologies , the mapping of the human genome and a wave of new biologic drug product approvals by the FDA .
The increased value of genetic testing in medicine has led to significant amount of precision medicine research , which has in turn resulted in the development of many targeted therapies and companion diagnostics , especially in the field of oncology , which has revolutionised the way patients are treated , and has given them a real chance at recovery . And it is seen that this trend is applied in other disease areas as well such as neurology , ophthalmology and metabolic disorders
From a drug discovery point of view , presence of genomic biomarkers is helping the research program to have a higher probability of success through more targeted approaches for patient selection . The FDA approval is also smoother with specific markers involved to explain the effectiveness of a drug . Overall , the application of genomics has made the drug discovery investments better in terms of returns .
What kind of business model has MedGenome employed in India ? How has been the growth financially as well as in terms of global expansion and partnerships ?
MedGenome provides an end-to-end integrated solutions for clinical
BIOVOICENEWS . COM 39
“ biotechnology companies, mostly perceived as generic manufacturers of blockbuster drugs without patent protection, are breaking the mould to innovate and develop products and technologies that are contributing to the advancement of global healthcare. With genomics being the future of healthcare, MedGenome has a great opportunity to be a global player. Sequencing (NGS) has significantly reduced the time and cost for genome analysis. These advances have highlighted its relevance in exploratory research and drug discovery, and have translated to a significant influx of capital into the molecular diagnostics firms due to their cutting edge technologies, the mapping of the human genome and a wave of new biologic drug product approvals by the FDA. We are in an age where Indian biotechnology companies, mostly perceived as generic manufacturers of blockbuster drugs without patent protection, are breaking the mould to innovate and develop products and technologies that are contributing to the advancement of global healthcare. What kind of analytical and algorithmic pipelines are being built by the company to interpret genomics data? What makes them different than the competition? MedGenome’s bioinformatics expertise offers end-to-end data analysis of next generation data using proprietary interpretation tools and algorithms. Our algorithm and analytical pipeline includes various in-house tools for comprehensive high-throughput annotation tool for analysis of germ line and somatic variants, high performance webbased tools for variant interpretation, tools to capture patient information including the clinical symptoms of the patients enabling clinicians to catalogue phenotype in formation of the patient in a systematic and controlled manner, software platform with a modular architecture for handling next-generation genomic sequencing pipeline from data generation to analysis and various proprietary databases such as the one with India population specific variant data and the one with millions of somatic cancer variant annotations. Our analysis components include data quality assessment, comprehensive custom analysis, interpretation of results for biological insights, and presentation of results to the customers in meaningful, easily readable report formats. Being a leader in diagnostics and research from India, MedGenome continuously refines and improves the pipeline to make the analysis more powerful. Which of the top disease areas are under the company's focus and why? MedGenome offers more than 278 tests across different disease areas: Cardiology, Metabolic disorders, Haematology, Ophthalmology, Neurology, Nephrology, Oncology, other rare disorders etc. We also address important research questions in hereditary diseases. As of now the company is extensively focusing on the problems that are affecting the population at large such as cancer, diabetes, cardiovascular diseases, eye disorders, neurological and blood disorders. We have developed specific gene panels that can identify mutations mostly found in the Indian population. How is the next generation sequencing shaping up, its future trends and effect on the overall drug discovery efforts? Genomics has seen rapid advances in the technology of decoding the DNA, triggering a revolution in our ability to understand the genetic and molecular basis of health and disease. The evolution of Next Generation The increased value of genetic testing in medicine has led to significant amount of precision medicine research, which has in turn resulted in the development of many targeted therapies and companion diagnostics, especially in the field of oncology, which has revolutionised the way patients are treated, and has given them a real chance at recovery. And it is seen that this trend is applied in other disease areas as well such as neurology, ophthalmology and metabolic disorders From a drug discovery point of view, presence of genomic biomarkers is helping the research program to have a higher probability of success through more targeted approaches for patient selection. The FDA approval is also smoother with specific markers involved to explain the effectiveness of a drug. Overall, the application of genomics has made the d Y\ݙ\H[\Y[]\[\\و]\˂][و\[\[[\“YY[YH[\YY[[XO’\Y[Hܛ[[X[H\[\[\\قؘ[^[[ۈ[\\\‚YY[YHݚY\[[ ]Y[[Yܘ]Y][ۜ܈[X[SՓPSUːBB